Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|August 26, 2014
Adjuvant Sorafenib for the Treatment of HCC (Phase III STORM Trial)
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.
Advertisement
Clinical Pearls
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.
- The phase III STORM trial was a randomized, double-blind, placebo-controlled study of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma.
- Results showed no difference in recurrence-free survival (33.4 months with sorafenib vs 33.8 with placebo).
- It remains to be seen if targeting cancer cells in the adjuvant setting with an anti-angiogenic drug is correct or if another concept might be more appropriate.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5